Otsuka Pharmaceutical Factory concludes an exclusive marketing agreement in Japan with B. Braun Aesculap for Actreen, an intermittent urological catheter

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara; "OPF") has concluded an exclusive marketing agreement in Japan with B. Braun Aesculap Japan Co., Ltd. (Head Office: Bunkyo-ku, Tokyo, Japan; President and Representative Director: Takeshi Fujiwara; "BBAJ") for the intermittent urological catheter Actreen, a medical device that BBAJ introduces into Japan. We plan to start marketing this product to medical institutions nationwide in mid-December this year.

This product is a single-use catheter consisting of a catheter (tube) and connector that can be used during self-catheterization in people who have lost urge to urinate or who usually have difficulty urinating. The surface of the catheter is coated with a hydrophilic lubricant, which can be used immediately after opening, and also contains a product with an integrated urine collection bag that can be used according to the patient's condition.

In the nursing care field in Japan, which has entered a super-aging society, the importance of excretion independence has been recognized and the need for excretory care is increasing, as evidenced by the review of the additional fee for excretion support in the 2021 revision of nursing care fees. In the event of residual urine or obstruction due to lower urinary tract obstruction, such as neurogenic bladder or prostatic hyperplasia, a method of clean intermittent drainage is widely used in which urine accumulated in the urinary bladder is catheterized through the urethral meatus at regular intervals to drain it out of the body, and a single-use hydrophilic product that is easy to use outside the hospital, such as at home care, has been desired.

BBAJ was established in 1986 as a Japanese subsidiary of B. Braun, a leading global healthcare company headquartered in Germany. With the vision of protecting and improving the well-being of people in Japan and around the world, they are contributing to Japanese medical care by delivering solutions covering diverse medical fields of B. Braun to Japanese healthcare settings.

The management vision of OPF is to be "The Best Partner in Clinical Nutrition." In addition, we are expanding our business areas to cover the entire healthcare process, such as prevention, diagnosis, treatment, and monitoring. Among these, we have been enhancing our products in the fields of urology and urination, including the marketing of Lilium^® α-200,^* a medical device that measures urinary bladder volume. We will continue to develop products that can contribute to excretion care for patients.

Based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated to contributing to the health of people around the world.

*Bladder volume ultrasound imaging device developed and sold by Lilium Otsuka, a subsidiary of OPF, since November 2015 (Medical device approval number: 227ADBZX00146000)

Product information